FeesSafety
Pluang+

ZenaTech wins $1M solar survey contracts with potential $2.5M follow-on revenue from US utility project

Market News
04 Nov 2026, 15:15 WIB
GlobeNewsWire
View Source
Bullish
ZenaTech wins $1M solar survey contracts with potential $2.5M follow-on revenue from US utility project

ZenaTech secured nearly $1 million in drone-based land surveying contracts for a U.S. utility's solar infrastructure project, with potential for an additional $2.5 million in follow-on revenue over two years. The contracts support a multi-year electrical grid upgrade, and ZenaTech aims to increase profit margins to 40%-60% by integrating AI and drones to improve efficiency. The company is also negotiating further Drone as a Service contracts and plans to test its AI software suite in 2027 to automate survey data processing. This marks progress in ZenaTech's strategy to grow recurring revenue through drone and AI technology in infrastructure projects.

ZenaTech's recent solar construction survey contracts provide context for technology sector activity. For readers following Technology stocks, here is Pluang's market snapshot as of Nov 04, 2026 20:01 WIB: Out of 150 priced US Technology stocks, 77 rose and 66 fell. Notable movers include FRSH at USD 12.86 (-9.12%), CDW at USD 161.42 (+7.78%), and VNET at USD 3.18 (+6.71%).

More News

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

Good Life Meds must stop unproven health and personalization claims for compounded Tirzepatide+ products.

The National Advertising Division (NAD) recommended that Good Life Meds discontinue claims about health benefits and personalization for its compounded Tirzepatide+ weight loss products after a challenge by Eli Lilly. NAD found that Good Life lacked ...

Market News
Bearish
27 minutes ago
Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin's Annamycin shows promising remission rates in AML trial, data to be presented at ASH 2026.

Moleculin Biotech announced that interim results from its Phase 2/3 trial of Annamycin for relapsed or refractory acute myeloid leukemia (AML) will be presented at the 2026 ASH Annual Meeting. The trial showed remission rates of 43% and 36% in two An...

Company Fundamentals
Bullish
27 minutes ago
ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

ANZ dental implants market to grow 5% CAGR, reaching $393M by 2033 driven by aging population and prosthetic demand

The Australia and New Zealand (ANZ) dental implants market, valued at $266 million in 2025, is projected to grow at a 5% CAGR to $393 million by 2033. Growth is driven by increasing demand for oral rehabilitation and prosthetic dentistry, especially ...

Market News
Bullish
27 minutes ago
New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

New study shows Asgard's tech induces cancer-fighting structures in tumors, boosting therapy success across 7 cancer types.

Asgard Therapeutics published a study in Immunity demonstrating its technology can reprogram tumor cells into dendritic cells, inducing cancer-fighting tertiary lymphoid structures (imgTLSs) across seven tumor types. This tumor-agnostic approach led ...

Others
Bullish
27 minutes ago
Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap expands onchain credit marketplace to finance film production without tokenizing assets

Cap, an onchain credit marketplace, is expanding into film and media financing by providing funding for the upcoming film Wake. This deal uses advances against anticipated film production tax credits, showing how Cap's underwriting model supports spe...

Market News
Bullish
27 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App